Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8569917 | 0.82 | GHSR (0.57) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL366547 | 0.80 | P2RX7 (0.55) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL19763793 | 0.79 | MTNR1A (0.49) | GHSRP2RX7MTNR1AMTNR1BFAAH | |
| SCHEMBL6584064 | 0.79 | P2RX7 (0.53) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL6584070 | 0.79 | P2RX7 (0.53) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL10249768 | 0.78 | HDAC8 (0.51) | — | |
| SCHEMBL11300748 | 0.78 | MTNR1A (0.47) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL7072069 | 0.78 | P2RX7 (0.52) | GHSRP2RX7MTNR1AMTNR1BNPY5R | |
| SCHEMBL406043 | 0.76 | MTNR1A (0.57) | GHSRP2RX7MTNR1AMTNR1BFAAH | |
| SCHEMBL15478536 | 0.76 | MTNR1A (0.57) | GHSRP2RX7MTNR1AMTNR1BFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142274-A1 | SUBSTITUTED ARYL COMPOUND | RAD51, FANCI, BLM | GHSR 3920/4885P2RX7 3898/4885MTNR1A 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.